drugset / Trial / NCT01227356
A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia
Phase 2
Completed
112 enrolled
Uppsala University
Karolinska University Hospital · collabUppsala University Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Patients with chronic myeloid leukemia in imatinib induced CHR are randomized between imatinib 400 mg daily and imatinib 400 mg daily + PegIntron 30 ug weekly. Primary endpoint: To compare at 12 months between the treatment arms the rate of Major Molecular Response (=99,9% tumour reduction) at 12 months
Timeline
- Start
- 2004-09
- Primary completion
- 2009-03
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 50 ug | Subcutaneous |
| Background | Imatinib | Small molecule | 400 mg | Oral |
Indications
No indication recorded.